Investigational Drug Information for Centhaquine
✉ Email this page to a colleague
What is the drug development status for Centhaquine?
Centhaquine is an investigational drug.
There have been 4 clinical trials for Centhaquine.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2022.
The most common disease conditions in clinical trials are Shock, Hypovolemia, and Acute Lung Injury. The leading clinical trial sponsors are Pharmazz, Inc. and [disabled in preview].
Summary for Centhaquine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2022-03-01) |
| Vendors | 41 |
Recent Clinical Trials for Centhaquine
| Title | Sponsor | Phase |
|---|---|---|
| Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in COVID-19 Patients With ARDS | Pharmazz, Inc. | Phase 2 |
| A Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent | Pharmazz, Inc. | Phase 3 |
| Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock | Pharmazz, Inc. | Phase 3 |
Clinical Trial Summary for Centhaquine
Top disease conditions for Centhaquine
Top clinical trial sponsors for Centhaquine
US Patents for Centhaquine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
